About Choline/ethanolamine kinase
Choline/ethanolamine kinase (CHKB) is a protein
from Homo sapiens identified by UniProt accession
Q9Y259, 395 residues long.
MolForge cross-references it against 0 known binders and
264 disease associations.
Target properties
| Protein name | Choline/ethanolamine kinase |
| UniProt accession | Q9Y259 |
| Gene | CHKB |
| Organism | Homo sapiens |
| Length | 395 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (264)
Diseases linked to this target (Open Targets).
- megaconial type congenital muscular dystrophy · score 0.72
- Congenital muscular dystrophy due to phosphatidylcholine biosynthesis defect · score 0.70
- neurodegenerative disease · score 0.39
- muscular dystrophy · score 0.28
- genetic disorder · score 0.19
- breast adenocarcinoma · score 0.18
- neurofibrillary tangles measurement · score 0.13
- Seizure · score 0.12
- Severe global developmental delay · score 0.12
- mean corpuscular volume · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y259-F1 | alphafold | PREDICTED | 85.10 | — |
Amino-acid sequence (395 residues)
MAAEATAVAG SGAVGGCLAK DGLQQSKCPD TTPKRRRASS LSRDAERRAY QWCREYLGGA WRRVQPEELR VYPVSGGLSN LLFRCSLPDH LPSVGEEPRE VLLRLYGAIL QGVDSLVLES VMFAILAERS LGPQLYGVFP EGRLEQYIPS RPLKTQELRE PVLSAAIATK MAQFHGMEMP FTKEPHWLFG TMERYLKQIQ DLPPTGLPEM NLLEMYSLKD EMGNLRKLLE STPSPVVFCH NDIQEGNILL LSEPENADSL MLVDFEYSSY NYRGFDIGNH FCEWVYDYTH EEWPFYKARP TDYPTQEQQL HFIRHYLAEA KKGETLSQEE QRKLEEDLLV EVSRYALASH FFWGLWSILQ ASMSTIEFGY LDYAQSRFQF YFQQKGQLTS VHSSS
Explore Choline/ethanolamine kinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets